Clinical Trials Browser

Phase 2 × INDUSTRY × Adenocarcinoma of Lung × Clear all

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT03184571 2025-09-25

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

99 enrolled 20 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03891173 2022-08-12

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Phase 2 Terminated

9 enrolled

Thoracic

Adenocarcinoma of Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02450903 2021-03-30

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Phase 2 Completed

20 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01218516 2020-08-20

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Phase 2 Completed

130 enrolled 11 charts

Thoracic

Adenocarcinoma of Lung

NCT01646125 2019-07-24

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Phase 2 Terminated

59 enrolled 9 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01685138 2019-03-26

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Phase 2 Completed

124 enrolled 18 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00511485 2015-02-27

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Phase 2 Completed

43 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01561456 2013-12-05

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung

Phase 2 Completed

100 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

Clinical Trials

HARMONIC

CDK4i

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung